The Column Group (TCG) led the round with participation from a select group of investors Primary sclerosing cholangitis (PSC) is a rare liver disease that irreparably damages the bile ducts, leading to bile acid dysregulation and, ultimately, severe liver damage Hyperemesis gravidarum (HG) is a rare, debilitating condition of pregnancy, characterized by intractable nausea and uncontrollable vomiting and frequent, serious complications There are no currently approved therapies for PSC or HG SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio), a privately held biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced a $122 million Series A financing led by TCG with participation from a select group of investors. NGM Bio will use the proceeds from the Series A financing to initiate a planned registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of PSC, and to complete a planned Phase 2 trial of NGM120, a GDF15/GFRAL antagonist, for the treatment of HG. Both trials are expected to begin in the fourth quarter of 2024. "At the beginning of this year, we unveiled our strategy to advance clinical development efforts for two serious, rare conditions characterized by significant unmet patient need. This Series A capital strengthens our financial position, enabling us to progress our planned registrational trial of aldafermin in primary sclerosing cholangitis and to evaluate NGM120 in a proof-of-concept study for hyperemesis gravidarum," said David J. Woodhouse, PhD, Chief Executive Officer at NGM Bio. "Having just completed a take-private ...